Elizabeth Phillips Archive — Page 2 of 3

September 29, 2022

Penicillin delabeling initiative expanding to more patient care areas

Efforts to correct mistaken or outdated penicillin allergy records are destined to spread to more patient care areas at Vanderbilt University Medical Center.

January 24, 2022

Vanderbilt recruiting children to study allergic responses to COVID-19 mRNA vaccines

Vanderbilt is conducting a clinical trial to determine risk and mechanisms of allergic reactions to COVID-19 Pfizer-BioNTech mRNA vaccine among children.

August 12, 2021

Certain drug exposures correlate with reduced COVID severity: study

Analyzing electronic health records (EHR) of 9,748 patients diagnosed with COVID-19, Cosmin Bejan, PhD, Elizabeth Phillips, MD, and colleagues at Vanderbilt University Medical Center asked whether COVID disease severity correlated with any drugs that happened to be taken by these patients in the months leading up to their diagnosis.

July 27, 2021

Using Patients’ Allergy History as Screening Tool for mRNA COVID-19 Vaccine Works Well: Study

A report of more than 23,000 health care workers and employees at Vanderbilt University Medical Center who received the Pfizer-BioNTech mRNA COVID-19 vaccine shows that a risk stratification screening mechanism for potential allergies to the vaccine worked exceedingly well as the vaccine program rolled out in December 2020.

October 1, 2020

Genes spell penicillin allergy risk

Studies using large DNA biobanks revealed genetic variants associated with penicillin allergy, the most common type of drug-induced allergic reaction.

May 6, 2020

New rule outlines when to challenge a penicillin allergy

According to the U.S. Centers for Disease Control and Prevention, fewer than 1% of the population is truly allergic to penicillin. The rest were never allergic to begin with or have outgrown their allergy — an estimated 80% of people with penicillin allergy lose their sensitivity to the drug within 10 years.